IL2 and systemic lupus erythematosus: In agreement with the role of IL-2 as an “anti-Tfh” agent, treatment of active Systemic Lupus Erythematosus (SLE) patients with low-dose rIL-2 resulted in reduced frequencies of Tfh cells in a recent clinical study by Jing He and colleagues (217), hence evidencing the therapeutic potential of IL-2 to prevent unwanted Tfh cell responses (Figure 2).